Eye changes in hyperlipoproteinaemia type Ii
Majewska, K.; Ciswicka-Sznajdermanowa, M.; Czechowicz-Janicka, K.
Klinika Oczna 47(4): 175-177
1977
ISSN/ISBN: 0023-2157 PMID: 853676 Document Number: 112399
Document emailed within 1 workday
Related Documents
Antonaci, S.; Jirillo, E.; Garofalo, A.R.; Polignano, A.; Resta, F.; Pugliese, P.; Capurso, A.; Bonomo, L. 1988: Cell-mediated immune response in patients with type IIa, type IIb and type IV primary hyperlipoproteinaemia Cytobios 54(218-219): 181-189Schade, R.W.; Laar A van't; Jansen, A.P. 1973: Treatment of type Ii hyperlipoproteinaemia with cholestyramine Netherlands Journal of Medicine 16(6): 254-259
Potter, J.M.; Macdonald, W.B. 1979: Primary type I hyperlipoproteinaemia--a metabolic and family study Australian and New Zealand Journal of Medicine 9(6): 688-693
Micheli, H.; Pometta, D.; Gustafson, A. 1980: Effects of fenofibrate in four types of hyperlipoproteinaemia and on apoproteins a and B in type IIa HLP La Nouvelle Presse Medicale 9(49): 3759-3762
Gariot, P.; Seurot, J.M.; Pointel, J.P.; Contet-Audonneau, J.L.; Gay, G.; Drouin, P.; Debry, G. 1982: The liver and primary type IV hyperlipoproteinaemia: a pathological study Human Nutrition. Clinical Nutrition 36(5): 351-361
Canetti, M.; Moreira, M.; Mas, R.; Illnait, J.; Fernandez, L.; Fernandez, J.; Diaz, E.; Castano, G. 1995: A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia International Journal of Clinical Pharmacology Research 15(4): 159-165
Sobra, J.; Heyrovský, A. 1972: Inborn errors of lipid metabolism. Familial hyperlipoproteinaemia type 3. Detection of heterozygotes Review of Czechoslovak Medicine 18(1): 34-39
Berger, G.M.; Van der Westhuyzen, J.H.; Huskisson, J.; Bonnici, F.; Henderson, H.E. 1982: Chylomicron and very-low-density lipoprotein levels in type I hyperlipoproteinaemia. The role of the liver in determining biochemical phenotype South African Medical Journal 61(8): 266-272
Hellström, K.; Einarsson, K. 1977: Bile acid metabolism in hyperlipoproteinaemia Clinics in Gastroenterology 6(1): 103-128
Lawrie, T.D.; Lorimer, A.R.; Ballantyne, D.; Jubb, J.S.; Morgan, H.G. 1975: The prevalence of hyperlipoproteinaemia in vascular disease Postgraduate Medical Journal 51(8): 7-15
Nye, E.R.; Sutherland, W.H.; Temple, W.a. 1980: The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate New Zealand Medical Journal 92(671): 345-349
Farid, N.R.; Dickinson, P.H.; MacNeal, I.F.; Anderson, J. 1974: Hyperlipoproteinaemia in peripheral arterial disease in the north of England Journal of Cardiovascular Surgery 15(3): 366-372
Ramaswami, P.K.; Senior, D.C. 1979: Klinefelter's syndrome with agenesis of kidney, diabetes, hyperlipoproteinaemia and stroke British Journal of Clinical Practice 33(5): 142-143
García-Gómez, C.; Martín-Martínez, M.ía.A.; Fernández-Carballido, C.; Castañeda, S.; González-Juanatey, C.; Sanchez-Alonso, F.; González-Fernández, M.ía.J.; Sanmartí, R.; García-Vadillo, J.ús.A.; Fernández-Gutiérrez, B.ín.; García-Arias, M.; Manero, F.J.; Senabre, J.é M.; Rueda-Cid, A.; Ros-Expósito, S.; Pina-Salvador, J.é M.; Erra-Durán, A.; Möller-Parera, I.; Llorca, J.; González-Gay, M.A. 2019: Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the Cardiovascular in Rheumatology (CARMA) project Clinical and Experimental Rheumatology 37(5): 774-782
Bower, S. 1982: Plasma protein binding of fentanyl: the effect of hyperlipoproteinaemia and chronic renal failure Journal of Pharmacy and Pharmacology 34(2): 102-106
Mast, T.Christopher.; Kierstead, L.; Gupta, S.B.; Nikas, A.A.; Kallas, E.G.; Novitsky, V.; Mbewe, B.; Pitisuttithum, P.; Schechter, M.; Vardas, E.; Wolfe, N.D.; Aste-Amezaga, M.; Casimiro, D.R.; Coplan, P.; Straus, W.L.; Shiver, J.W. 2010: International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials Vaccine 28(4): 950-957
McKean, D.J.; Podzorski, R.P.; Bell, M.P.; Nilson, A.E.; Huntoon, C.J.; Slack, J.; Dower, S.K.; Sims, J. 1993: Murine T helper cell-2 lymphocytes express type I and type II IL-1 receptors, but only the type I receptor mediates costimulatory activity Journal of Immunology 151(7): 3500-3510
Berntorp, E.; Jarevi, G.; Vedback, A.; Nilsson, I.M. 1986: Living adenovirus type 4 vaccine human t lymphotropic virus type iii antibodies in swedish hemophiliacs in relation to type and dosage of factor concentrate Thrombosis Research (Suppl 6): 18
Rathore, A.; Chatterjee, A.; Sivarama, P.; Yamamoto, N.; Singhal, P.K.; Dhole, T.N. 2009: Association of CCR5-59029 A/G and CCL3L1 copy number polymorphism with HIV type 1 transmission/progression among HIV type 1-seropositive and repeatedly sexually exposed HIV type 1-seronegative North Indians Aids Research and Human Retroviruses 25(11): 1149-1156
Su, Z.Z.; Leon, J.A.; Jiang, H.; Austin, V.N.; Zimmer, S.G.; Fisher, P.B. 1993: Wild-type adenovirus type 5 transforming genes function as transdominant suppressors of oncogenesis in mutant adenovirus type 5 transformed rat embryo fibroblast cells Cancer Research 53(8): 1929-1938